Skip to main content
Global Life Sciences Update

Major Medicare Part B Payment Changes Finalized for 2027

November 19, 2026

The Centers for Medicare & Medicaid Services (CMS or Agency) recently issued two annual final rules: the CY 2027 Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Final Rule with Comment Period (OPPS-ASC Final Rule) and the CY 2027 Medicare Physician Fee Schedule Final Rule (PFS Final Rule).

The final rules include several policy updates, including substantial reductions in reimbursement for 340B-acquired drugs in the hospital outpatient setting, new Medicare Part D 340B claims reporting requirements, updates for radiopharmaceutical and skin substitute reimbursement, and revisions to remote patient and therapeutic monitoring policies, among others. 

Most provisions of the final rules are scheduled to take effect on January 1, 2027. Stakeholders should review the finalized policies and accompanying addenda, including changes to APC assignments and payment rates, to assess their implications. Although the PFS Final Rule is not subject to a comment period, CMS is accepting comments on certain aspects of the OPPS-ASC Final Rule through January 4, 2027, including interim payment classifications and assignments for certain new and revised HCPCS codes.

 

OPPS-ASC Final Rule Provisions

1. 340B Program

a. Reduced Payments for 340B-Acquired Drugs. CMS finalized its proposal to lower reimbursement for drugs that 340B hospitals acquire at the 340B price from the current ASP plus 6% but modified the methodology used to calculate the reduction. Rather than adopting the proposed rate of ASP minus 33.4%, CMS finalized a rate of ASP minus 28%.

CMS also finalized reimbursement at WAC minus 28% when ASP is unavailable and at 64.53% of AWP when WAC is unavailable (calculated by applying an approximate 28% reduction to AWP).

CMS declined to exclude certain categories of drugs, including therapeutic radiopharmaceuticals, from the revised payment methodology, emphasizing its preference for a consistent approach across products. However, CMS clarified that the methodology would not apply to 340B-acquired drugs with pass-through status, citing the statutory payment requirements applicable to those products.

b. 340B Remedy Offset. CMS finalized its proposal to accelerate the offset of $7.8 billion in payments made to hospitals to remedy reimbursement reductions from 2018 to 2022 that the Supreme Court found unlawful. However, rather than increasing the annual payment reduction for nondrug items and services from 0.5% to the proposed 3%, CMS finalized a 2% reduction beginning January 1, 2027. CMS explained that this modification responds to commenters’ concerns regarding the financial impact of the accelerated offset on hospitals, particularly in light of the financial pressures hospitals state they have experienced in recent years.

2. Diagnostic Radiopharmaceuticals

a. MUC-Based Reimbursement. CMS finalized its proposal to continue using mean unit cost (MUC) to determine reimbursement for diagnostic radiopharmaceuticals with per-day costs exceeding a specified threshold, noting that most commenters supported the proposal. CMS noted that some commenters urged CMS to move to ASP-based reimbursement, but CMS expressed concern with the lack of reliable ASP being reported for these products.

Based on updated Producer Price Index (PPI) data, CMS reduced the threshold from the proposed $655 to $635. CMS also published a revised table identifying 31 diagnostic radiopharmaceuticals that exceed the $635 threshold and will therefore be reimbursed using MUC in CY 2027.

b. Voluntary ASP Reporting. CMS finalized its proposal to continue to state that ASP reporting is voluntary for diagnostic radiopharmaceuticals reimbursed under OPPS in CY 2027. However, CMS encouraged manufacturers to report ASP and indicated that it would continue evaluating its authority to require such reporting in future rulemakings.

3. Skin Substitutes

CMS finalized its proposal to maintain reimbursement for nearly all sheet-form skin substitutes at $127.14 per cm² without further changes to their reimbursement.

For non-sheet-form skin substitutes, CMS finalized its proposal to continue bundling product costs into application codes, citing differences in how these products are manufactured, applied, and measured compared to sheet-form products. However, CMS departed from its proposal to provide no separate payment for application services, instead finalizing separate reimbursement for nonsheet skin substitute application codes G0681 and G0683. CMS explained that separate payment would promote parity with reimbursement for the application of sheet-form products and better account for the resources associated with applying nonsheet products.

PFS Final Rule Provisions

1. Medicare IRA Inflation Rebate Updates

a. Mandatory Medicare Part D 340B Claims Reporting. CMS finalized its proposal to require Medicare-enrolled providers and suppliers that qualify as 340B covered entities to report Part D claims to the Medicare Part D Claims Data 340B Repository for dates of service beginning January 1, 2027. Covered entities must submit specified claim-level information, including claims involving contract pharmacy arrangements and retrospective replenishment, on a quarterly basis and certify the completeness and accuracy of their submissions.

In response to stakeholders’ implementation concerns, CMS delayed the initial reporting deadline to September 30, 2027, for claims with dates of service during the first two quarters of CY 2027. Subsequent quarterly submissions generally will be due within one calendar quarter after the close of the applicable quarter. CMS also clarified that AIDS Drug Assistance Programs (ADAPs) are not subject to the reporting requirement because they are not Medicare-enrolled providers or suppliers.

Importantly, CMS stated that it will not use the reported data for purposes of the Part D inflation rebates at this time. Instead, CMS will continue using its existing Prescriber-Pharmacy Methodology to exclude 340B units from rebate calculations while evaluating the reliability of Repository data for potential future use.

b. Medicare Part B First Marketed Date. CMS finalized its proposal, with a nonsubstantive technical modification, to establish a hierarchy of data sources for determining a drug's “first marketed date” when ASP data are unavailable. This date determines the benchmark period used to calculate inflation-adjusted payment amounts under the Medicare Part B Drug Inflation Rebate Program. Under the finalized policy, CMS will continue to rely on ASP data where available. However, if ASP data do not include a first marketed date for any NDC-11 associated with an FDA application number ever linked to the relevant billing and payment code, CMS will instead use an alternative public source, such as the FDA NDC Directory. If the date is unavailable from either source, CMS will use the FDA approval date listed in the Orange Book or Purple Book. CMS declined requests to use the Medicaid Drug Rebate Program “market date” or establish a separate manufacturer attestation process, concluding that its finalized approach provides an appropriate basis for determining the first marketed date.

2. Skin Substitutes

CMS finalized its proposals to establish national pricing for non-sheet-form skin substitutes at $127.14 per cm², the same as sheet skin substitutes, and provide separate reimbursement for their application. CMS clarified that the per cm² payment rate applies regardless of how a product is packaged or measured (e.g., per mL, per cc, or per mg).

3. PFS Conversion Factors

CMS finalized CY 2027 PFS conversion factors of $32.9548 for qualifying Alternative Payment Model (APM) participants and $32.6286 for nonqualifying APM participants, representing decreases of 1.83% and 2.31%, respectively, from CY 2026. Despite statutory payment updates of 0.75% and 0.25%, respectively, the expiration of the temporary 2.5% payment increase for CY 2026 and a negative 0.12% budget neutrality adjustment result in lower conversion factors for CY 2027.

4. Reimbursement Methodology Changes

CMS finalized several changes to the methodology for calculating practice expense (PE) relative value units (RVUs), which account for the direct and indirect costs of furnishing physician services. Because PE RVUs are calculated on a relative, budget-neutral basis, these changes will result in higher reimbursement for some services and lower reimbursement for others. Stakeholders should closely review the addenda to the PFS Final Rule to assess the effect on relevant codes.

a. Practice Expense Stabilization Adjustment. To limit year-to-year fluctuations resulting from changes to the PE methodology, CMS finalized a stabilization adjustment that generally caps annual increases or decreases in a code's PE RVUs at 5%. The adjustment excludes new or revised codes, newly nationally priced codes, and revalued codes. CMS retained these exclusions and the 5% threshold despite comments requesting changes, citing the need to balance payment stability with more accurate PE valuations. CMS also published a public use file identifying the codes subject to the adjustment.

b. Reconsideration of AMA/RUC Role in Physician Payment. CMS did not finalize changes to the CPT or AMA/Specialty Society Relative Value Scale Update Committee (RUC) processes but indicated that potential reforms remain under consideration. In the PFS proposed rule, CMS had sought comment on the role of the American Medical Association (AMA) in developing CPT codes and the RUC’s recommendations in valuing physician services, citing concerns about reliance on recommendations from organizations with potential financial interests in payment rates. Commenters suggested reforms involving greater transparency, increased use of empirical data, changes to RUC membership, and alternative valuation processes. In the PFS Final Rule, CMS encouraged organizations submitting valuation recommendations to incorporate empirical data, market-based information, and clinical outcomes and indicated that it may establish additional submission requirements through future rulemaking.

5. Remote Patient and Therapeutic Monitoring

CMS finalized several, but not all, of its proposed changes to remote patient monitoring (RPM) and remote therapeutic monitoring (RTM) requirements, including the following:

Direct Employment Requirement. CMS finalized its proposal to require RPM and RTM services to be furnished by employees of the practice. This will be a significant change for many providers, as currently such services are often furnished by individuals employed or contracted with outside vendors. In recognition of the significance of this change, CMS delayed implementation by two years, until January 1, 2029. CMS also confirmed that the requirement would not prohibit practitioners from using third-party vendors that provide software, devices, and other technical support rather than staff time.” CMS stated that it would also provide additional guidance regarding permissible employment arrangements.

  • Established Patient Requirement for RTM. CMS finalized its proposal to require patients to be established patients of the practice before initiating RTM services, which was already a requirement for RPM. CMS explained that this requirement helps ensure that practitioners have sufficient information about a patient’s medical status and needs before ordering RTM services.
  • Initiating Visit Requirements for RPM and RTM. CMS finalized its proposal to require practitioners to discuss RPM or RTM services with patients during a face-to-face visit before initiating monitoring, meaning that telehealth appointments will not be sufficient. However, CMS did not establish a specific timeframe between the initiating visit and the commencement of monitoring services, provided that RPM or RTM was discussed during the visit.” CMS also noted that a patient can become an established patient through the performance of the initiating visit.
  • Revaluation of Codes. CMS finalized certain proposed revaluations of RPM and RTM codes that generally reduced reimbursement while declining to adopt others in response to comments regarding resource utilization.No Bundling of RPM and RTM. CMS declined to finalize its proposal to establish bundling codes covering both RPM and RTM.

6. Other Changes

CMS also finalized several, but not all, of its proposed changes affecting evaluation and management (E/M) services, clinical trials, and laboratory testing, including the following:

  • E/M Updates. CMS finalized new coding and payment policies addressing several types of E/M services, including (1) a modifier recognizing care coordination and associated reimbursement, (2) codes for shared medical appointments, and (3) codes for visits related to vaccine adverse effects.
  • Multiple Service Payment Reduction. CMS finalized a payment reduction for certain E/M services furnished on the same day as a procedure with a zero-day global period, citing efficiencies associated with providing multiple services on the same day.
  • Payments for Counseling on Clinical Trials. CMS declined to finalize its proposal to establish a new code for clinical trial counseling services. Despite general support by commentors, CMS noted that there were “differing views on code structure, billing eligibility, valuation, telehealth availability, and documentation requirements.”
  • Payment for Algorithmic Analysis in Laboratory Testing. CMS finalized its proposal to shift reimbursement for certain Software as a Medical Service (SaMS) from the Clinical Laboratory Fee Schedule to the PFS, allowing CMS to more actively manage payment rates for these services.

Attorney Advertising—Sidley Austin LLP is a global law firm. Our addresses and contact information can be found at www.sidley.com/en/locations/offices.

Sidley provides this information as a service to clients and other friends for educational purposes only. It should not be construed or relied on as legal advice or to create a lawyer-client relationship. Readers should not act upon this information without seeking advice from professional advisers. Sidley and Sidley Austin refer to Sidley Austin LLP and affiliated partnerships as explained at www.sidley.com/disclaimer.

© Sidley Austin LLP